# Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant

> **NCT04104438** · PHASE4 · COMPLETED · sponsor: **Fady M Kaldas, M.D., F.A.C.S.** · enrollment: 71 (actual)

## Conditions studied

- Asses Immunosuppression Modulation on Renal Recovery Post LT

## Interventions

- **DRUG:** Basiliximab 20 MG

## Key facts

- **NCT ID:** NCT04104438
- **Lead sponsor:** Fady M Kaldas, M.D., F.A.C.S.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-15
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04104438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04104438, "Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT04104438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*